Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Former Icahn MD’s Sarissa Capital Discloses 6.2% of Ariad Pharmaceuticals

According to a new filing with the SEC, Sarissa Capital Management now holds around 11.5 million shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), with an aggregate value of some $43.6 million, at the current stock price of the company. The position held by Sarissa  amasses about 6.2% of Ariad’s common stock.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Alex Denner used to work for Carl Icahn between 2006 and 2011. Sarissa Capital is an activist healthcare focused hedge fund with a long bias. The fund was launched earlier in 2013.

Disclosure: none

Recommended Reading:

Dan Gold’s QVT Ups Stake in Oncothyreon to 5.8%

David Blood and Al Gore Decrease Position in Kingspan Group to 8.7%

The 10 Main Hedge Fund Moves of the Past Seven Days